Company intelligence
Herantis Pharma Plc.
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s.
About Herantis Pharma Plc.
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients. Herantis is listed on the Nasdaq First North Growth Market Finland.
Verified activity
Signals from Herantis Pharma Plc.
1 published signal